Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LATS1 | O95835 | 5/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.31 |
| ▸ | KDM6B | O15054 | 2/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2453241 | 0.94 | LATS1 (0.33) | LATS1KDM5ACYP3A4KAT2BKDM6B | |
| SCHEMBL2369636 | 0.90 | KDM5A (0.39) | LATS1KDM5A | |
| SCHEMBL14562492 | 0.81 | KDM4C (0.44) | KDM5AKAT2BKDM6BKDM4C | |
| SCHEMBL14562434 | 0.79 | KDM5A (0.40) | KDM5AKAT2BKDM6BKDM4C | |
| SCHEMBL2833404 | 0.78 | MEN1 (0.33) | CYP3A4KAT2BTLR8 | |
| SCHEMBL2370142 | 0.75 | CALCA (0.36) | KAT2BKDM6BKDM4CTLR8 | |
| SCHEMBL14562442 | 0.74 | KDM5A (0.40) | KDM5AKAT2BKDM6BKDM4C | |
| SCHEMBL2453240 | 0.71 | KDM5A (0.34) | KDM5ACYP3A4KAT2B | |
| SCHEMBL2370205 | 0.69 | TDP1 (0.34) | LATS1KDM5A | |
| SCHEMBL2453838 | 0.69 | KDM4E (0.38) | KAT2BTLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130190499-A1 | Azaisoquinolinone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2013-07-25 | — | — | US | disclosed |
| EP-2545053-A1 | AZAISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. Lundbeck A/S (DK) | 2013-01-16 | — | — | EP | disclosed |
| US-20110224247-A1 | AZAISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2011-09-15 | — | — | US | disclosed |
| WO-2011110183-A1 | AZAISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224247-A1 | AZAISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | KCNQ3, KCNK3, KCND3 | LATS1 3046/4885KDM5A 707/4885CYP3A4 1693/4885 |
| US-20130190499-A1 | Azaisoquinolinone derivatives as NK3 antagonists | KCNQ3, KCNK3, KCND3 | LATS1 3046/4885KDM5A 707/4885CYP3A4 1693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.